E-ISSN 2534-9821
 
2023, Vol: 7, Issue: 11
7 / 11Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Copyright Transfer Form

Mini Review
Online Published: 04 Feb 2020
 


Neutrophil to lymphocyte ratio in immunotherapy for malignancies

Bassim Kobrossy.


Abstract
In the quest for a simple and effective biomarker for PD-1 antibody efficacy many candidates have emerged. The simplest one is the ratio between neutrophils and lymphocytes (NLR) in peripheral blood. Since 2012 the emergence of checkpoint inhibitor therapy has introduced a new paradigm in cancer therapy, adding a powerful tool in the oncology treatment armamentarium. The progress achieved in clinical trials have revealed efficacy in different tumor types and with different immunotherapy combinations. However optimal duration of therapy, optimal dose, optimal schedule, are for the most part unknown. In this review we will discuss the utility of information obtained from the peripheral blood CBC as a contributor to solving this question.
 

Key words: pd1, checkpoint inhibitors, neutrophil to lymphocyte ratio


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Bassim Kobrossy
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Bassim Kobrossy. Neutrophil to lymphocyte ratio in immunotherapy for malignancies. Int J Med Rev Case Rep. 2020; 4(1): 11-13. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology

Web Style

Bassim Kobrossy. Neutrophil to lymphocyte ratio in immunotherapy for malignancies. https://www.mdpub.net/?mno=82035 [Access: October 14, 2024]. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology

AMA (American Medical Association) Style

Bassim Kobrossy. Neutrophil to lymphocyte ratio in immunotherapy for malignancies. Int J Med Rev Case Rep. 2020; 4(1): 11-13. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology


Vancouver/ICMJE Style

Bassim Kobrossy. Neutrophil to lymphocyte ratio in immunotherapy for malignancies. Int J Med Rev Case Rep. (2020), [cited October 14, 2024]; 4(1): 11-13. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology


Harvard Style

Bassim Kobrossy (2020) Neutrophil to lymphocyte ratio in immunotherapy for malignancies. Int J Med Rev Case Rep, 4 (1), 11-13. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology


Turabian Style

Bassim Kobrossy. 2020. Neutrophil to lymphocyte ratio in immunotherapy for malignancies. International Journal of Medical Reviews and Case Reports, 4 (1), 11-13. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology


Chicago Style

Bassim Kobrossy. "Neutrophil to lymphocyte ratio in immunotherapy for malignancies." International Journal of Medical Reviews and Case Reports 4 (2020), 11-13. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology


MLA (The Modern Language Association) Style

Bassim Kobrossy. "Neutrophil to lymphocyte ratio in immunotherapy for malignancies." International Journal of Medical Reviews and Case Reports 4.1 (2020), 11-13. Print. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology


APA (American Psychological Association) Style

Bassim Kobrossy (2020) Neutrophil to lymphocyte ratio in immunotherapy for malignancies. International Journal of Medical Reviews and Case Reports, 4 (1), 11-13. doi:10.5455/IJMRCR.Neutrophil-Lyphocyte-Ratio-oncology


Author LoginReviewer LoginAbout PublisherEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessAuthor's Rights and ObligationsPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About International Journal of Medical Reviews and Case Reports

International Journal of Medical Reviews and Case Reports  (Int J Med Rev Case Rep)ISSN: 2534-9821The International Journal of Medical Reviews and Ca ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the International Journal of Medical Reviews and Case Reports editorial office as follows:

Bulgarian Association of Young Surgeons (BAYS);

National Center of Public Health and Analyses (NCPHA), floor 2, office № 31,  Sofia 1431, Bulgaria.

inkov@journalmedica.com

Financial department is managed by International Sci Ink Press. 

It is a company registered in Bulgaria with registered no. 205414288 and registered address at 57 Antim I str., Vazrazhdane, Sofia, 1303, Bulgaria.

Tel: +359883427500